Ebrahim S. Delpassand, MD, FACNM
Chairman and Medical Director
Excel Diagnostics and Nuclear Oncology Center, Houston, Texas
Founder, Chairman of the Board, and CEO, RadioMedix, Houston, Texas
Ebrahim S. Delpassand, MD, FACNM, Chairman and Medical Director at Excel Diagnostics & Nuclear Oncology Center in Houston, Texas and founder, Chairman of the Board, and CEO of Radiomedix in Houston, is the featured guest for Luncheon with the Experts on Thursday, April 8, 2021.
A nuclear medicine specialist, Dr. Delpassand was formerly deputy chairman, associate professor, chief of clinical nuclear medicine and director of therapeutic nuclear medicine at MD Anderson Cancer Center in Houston, Texas. His prestigious credentials and extensive experience include the disciplines of therapeutic nuclear medicine, nuclear cardiology, monoclonal antibody imaging and positron emission tomography.
Resources:
Excel Diagnostics & Nuclear Oncology Center: https://exceldiagnostics.com/
RadioMedix: https://radiomedix.com/
Neuroendocrine Cancer Clinical Trials at Excel Diagnostics: https://exceldiagnostics.com/pages/research-1
- Phase 1 Study of AlphaMedix™ in Adult Subjects With SSTR (+) NET
- Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET. (PUTNET)
- Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients (COMPETE)
PET/CT Scanning at Excel Diagnostics, including FDG PET/CT, DETECTNET (Cu 64 DOTATATE) and Ga-68 NETSPOT):
PRRT with Lu-177 Lutathera at Excel Diagnostics:
Selected Publications:
64 Cu-DOTATATE PET/CT for Imaging Patients with Known or Suspected Somatostatin Receptor-Positive Neuroendocrine Tumors: Results of the First U.S. Prospective, Reader-Masked Clinical Trial, https://pubmed.ncbi.nlm.nih.gov/31924723/
Preclinical investigation of 212Pb-DOTAMTATE for peptide receptor radionuclide therapy in a neuroendocrine tumor model, https://mct.aacrjournals.org/content/18/5/1012.long
Long-Term Survival, Toxicity Profile, and role of F-18 FDG PET/CT scan in Patients with Progressive Neuroendocrine Tumors Following Peptide Receptor Radionuclide Therapy with High Activity In-111 Pentetreotide, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3364554/
Peptide Receptor Radionuclide Therapy with Lu-177 Octreotate in patients with Somatostatin Receptor Expressing Neuroendocrine Tumors: Six Years Assessment, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7733354/
Selected Press Coverage:
RadioMedix & Curium Announce Permanent HCPCS Code for Detectnet™ (copper Cu 64 dotatate injection), https://www.curiumpharma.com/2021/01/26/radiomedix-curium-announce-permanent-hcpcs-code-for-detectnet-copper-cu-64-dotatate-injection/
RadioMedix and Curium Announce FDA Approval of Detectnet (copper Cu 64 dotatate injection) in the U.S., https://www.curiumpharma.com/2020/09/08/radiomedix-and-curium-announce-fda-approval-of-detectnet-copper-cu-64-dotatate-injection-in-the-u-s/
Who’s Actually Using ‘Right-To-Try’ Laws? A Texas Oncologist Explains his Experience, https://www.raps.org/regulatory-focus%E2%84%A2/news-articles/2017/8/who-s-actually-using-right-to-try-laws-a-texas-oncologist-explains-his-experience
